Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 284

Sort by

Sort Order Select

Journal Articles

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

Rami Komrokji, Virginia Volpe, Onyee Chan, Najla Al Ali, David Swoboda, Andrew Kuykendall, Eric Padron, David A. Sallman

Blood (2021) 138 (11): 989–992.

https://doi.org/10.1182/blood.2021010831

Published: 2021

Journal Articles

Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood . 2020;136(2):157-170.

Blood (2021) 137 (21): 3003.

https://doi.org/10.1182/blood.2021012067

Published: 2021

Journal Articles

Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms

Justin Taylor, Xiaoli Mi, Khrystyna North, Moritz Binder, Alexander Penson, Terra Lasho, Katherine Knorr, Michael Haddadin, Bo Liu, Joseph Pangallo, Salima Benbarche, Daniel Wiseman, Ayalew Tefferi, Stephanie Halene, Yang Liang, Mrinal M. Patnaik, Robert K. Bradley, Omar Abdel-Wahab

Blood (2020) 136 (13): 1477–1486.

https://doi.org/10.1182/blood.2020006868

Published: 2020

Includes: Supplemental data

Journal Articles

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Blood (2020) 136 (2): 157–170.

https://doi.org/10.1182/blood.2020004850

Published: 2020

Journal Articles

SF3B1 : the lord of the rings in MDS

Laura Palomo, Francesc Solé

Blood (2020) 136 (2): 149–151.

https://doi.org/10.1182/blood.2020005719

Published: 2020

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations

Joseph Pangallo, Jean-Jacques Kiladjian, Bruno Cassinat, Aline Renneville, Justin Taylor, Jacob T. Polaski, Khrystyna North, Omar Abdel-Wahab, Robert K. Bradley

Blood (2020) 135 (13): 1032–1043.

https://doi.org/10.1182/blood.2019002894

Published: 2020

Includes: Supplemental data

Journal Articles

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Blood (2019) 134 (21): 1821–1831.

https://doi.org/10.1182/blood.2019001187

Published: 2019

Includes: Supplemental data

Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Blood (2019) 134 (Supplement_1): 564.

https://doi.org/10.1182/blood-2019-129189

Published: 2019

Journal Articles

The Biological Inferences from the Ranking of SF3B1 Mutations in the Clonal Hierarchy of Myeloid Neoplasia

Hassan Awada, Jibran Durrani, Ashwin Kishtagari, MBBS, Vera Adema, PhD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, Bartlomiej Przychodzen, Jack Khouri, MD, Heesun J. Rogers, MD PhD, Manja Meggendorfer, PhD, Anjali S. Advani, MD, Aziz Nazha, MD, Torsten Haferlach, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 5411.

https://doi.org/10.1182/blood-2019-128965

Published: 2019

Journal Articles

Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications

Vera Adema, PhD, Laura Palomo, Cassandra M Kerr, MS, Wencke Walter, PhD, Bartlomiej Przychodzen, Stephan Hutter, PhD, Thomas Laframboise, PhD, María Díez-Campelo, MD PhD, Mar Mallo, PhD, Aziz Nazha, MD, Blanca Xicoy, MD MSc, Manja Meggendorfer, PhD, Hetty E. Carraway, MD MBA, Claudia Haferlach, MD, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Torsten Haferlach, MD, Francesc Sole, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 4221.

https://doi.org/10.1182/blood-2019-129292

Published: 2019

Journal Articles

SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML

Blood (2019) 134 (Supplement_1): 4224.

https://doi.org/10.1182/blood-2019-124458

Published: 2019

Journal Articles

High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster

Blood (2019) 134 (Supplement_1): 3720.

https://doi.org/10.1182/blood-2019-129276

Published: 2019

Journal Articles

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome

Ali Sakhdari, MD MSc, Caleb Class, PhD, Guillermo Montalban-Bravo, MD, Koji Sasaki, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Joseph D. Khoury, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, L. Jeffrey Medeiros, MD, Rashmi Kanagal-Shamanna, MD

Blood (2019) 134 (Supplement_1): 3016.

https://doi.org/10.1182/blood-2019-131774

Published: 2019

Journal Articles

Identification of an Expanded Immature Cell Population in Human Bone Marrow during Erythroid Responses to ESA Treatment

Isabel Juliana F Hofman, PhD, Teresa Mortera-Blanco, PhD, Sigita Venckute Larsson, Sten Eirik Waelgaard Jacobsen, MD PhD, Petter S Woll, PhD, Marios Dimitriou, PhD, Eva Hellstrom Lindberg, MD PhD

Blood (2019) 134 (Supplement_1): 2993.

https://doi.org/10.1182/blood-2019-130065

Published: 2019

Journal Articles

Molecular Genetics and Prognosis in Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Daniel Helbig, MD, Ghaith Abu Zeinah, MD, Erica B Bhavsar, BS, Richard R. Furman, MD, John N. Allan, MD

Blood (2019) 134 (Supplement_1): 3025.

https://doi.org/10.1182/blood-2019-125426

Published: 2019

Journal Articles

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Yasunobu Nagata, MD PhD, Hideki Makishima, MD PhD, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Hassan Awada, Vera Adema, PhD, Valeria Visconte, PhD, Sudipto Mukherjee, MD PhD MPH, Thomas Laframboise, PhD, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Seishi Ogawa, MD PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2992.

https://doi.org/10.1182/blood-2019-128893

Published: 2019

Journal Articles

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

Rami S. Komrokji, MD, David A Sallman, MD, Najla Al Ali, M.Sc, Andrew T Kuykendall, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Eric Padron, MD, Alan F. List, MD

Blood (2019) 134 (Supplement_1): 3001.

https://doi.org/10.1182/blood-2019-127462

Published: 2019

Journal Articles

Impact of U2AF1 Mutations on Clinical Characteristics and RNA Splicing in Myelodysplastic Syndromes (MDS)

Bing Li, MD, Jinqin Liu, Tiejun Qin, Zefeng Xu, MD, Gang Huang, PhD, Zhijian Xiao, MD

Blood (2019) 134 (Supplement_1): 2979.

https://doi.org/10.1182/blood-2019-126346

Published: 2019

Journal Articles

Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease

Manja Meggendorfer, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 3360.

https://doi.org/10.1182/blood-2019-126580

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood . 2020;136(2):157-170.

Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

SF3B1 : the lord of the rings in MDS

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

The Biological Inferences from the Ranking of SF3B1 Mutations in the Clonal Hierarchy of Myeloid Neoplasia

Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications

SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML

High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome

Identification of an Expanded Immature Cell Population in Human Bone Marrow during Erythroid Responses to ESA Treatment

Molecular Genetics and Prognosis in Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

Impact of U2AF1 Mutations on Clinical Characteristics and RNA Splicing in Myelodysplastic Syndromes (MDS)

Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only